CY1107254T1 - Μη πεπτιδικοι ανταγωνιστες της ωραδυκινινης και φαρμακευτικες συνθεσεις αυτων - Google Patents

Μη πεπτιδικοι ανταγωνιστες της ωραδυκινινης και φαρμακευτικες συνθεσεις αυτων

Info

Publication number
CY1107254T1
CY1107254T1 CY20081100314T CY081100314T CY1107254T1 CY 1107254 T1 CY1107254 T1 CY 1107254T1 CY 20081100314 T CY20081100314 T CY 20081100314T CY 081100314 T CY081100314 T CY 081100314T CY 1107254 T1 CY1107254 T1 CY 1107254T1
Authority
CY
Cyprus
Prior art keywords
peptide
oradykinin
components
pharmaceutical compositions
compounds
Prior art date
Application number
CY20081100314T
Other languages
English (en)
Inventor
Patrizia Felicetti
Christopher Ingo Fincham
Alessandro Giolitti
Carlo Alberto Maggi
Laura Quartara
Cristina Rossi
Original Assignee
Instituto Luso Farmaco D'italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Luso Farmaco D'italia S.P.A. filed Critical Instituto Luso Farmaco D'italia S.P.A.
Publication of CY1107254T1 publication Critical patent/CY1107254T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Οι μη πεπτιδικές ενώσεις, που είναι δραστικές ως επιλεκτικοί ανταγωνιστές του Β2 υποδοχέα της βραδυκινίνης (ΒΚ). Οι ενώσεις χαρακτηρίζονται χημικά από την παρουσία ενός αμινοξέος άλφα υποκατεστημένου με μια κυκλική ομάδα και με μια τετρααλκυλωμμωνιακή ομάδα.
CY20081100314T 2004-10-15 2008-03-20 Μη πεπτιδικοι ανταγωνιστες της ωραδυκινινης και φαρμακευτικες συνθεσεις αυτων CY1107254T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001963A ITMI20041963A1 (it) 2004-10-15 2004-10-15 "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP05789989A EP1799214B8 (en) 2004-10-15 2005-09-27 Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom

Publications (1)

Publication Number Publication Date
CY1107254T1 true CY1107254T1 (el) 2012-11-21

Family

ID=35810869

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100314T CY1107254T1 (el) 2004-10-15 2008-03-20 Μη πεπτιδικοι ανταγωνιστες της ωραδυκινινης και φαρμακευτικες συνθεσεις αυτων

Country Status (30)

Country Link
US (1) US7645759B2 (el)
EP (1) EP1799214B8 (el)
JP (1) JP4980917B2 (el)
CN (1) CN101039671B (el)
AR (1) AR051392A1 (el)
AT (1) ATE381931T1 (el)
AU (1) AU2005293881B2 (el)
BR (1) BRPI0515983A (el)
CA (1) CA2583920C (el)
CY (1) CY1107254T1 (el)
DE (1) DE602005004039T2 (el)
DK (1) DK1799214T3 (el)
EA (1) EA010913B1 (el)
ES (1) ES2299090T3 (el)
GE (1) GEP20115322B (el)
HK (1) HK1107263A1 (el)
HR (1) HRP20080107T3 (el)
IL (1) IL182494A (el)
IT (1) ITMI20041963A1 (el)
MA (1) MA29007B1 (el)
MX (1) MX2007004297A (el)
NO (1) NO339805B1 (el)
NZ (1) NZ554469A (el)
PL (1) PL1799214T3 (el)
PT (1) PT1799214E (el)
RS (1) RS50563B (el)
SI (1) SI1799214T1 (el)
UA (1) UA86091C2 (el)
WO (1) WO2006040004A1 (el)
ZA (1) ZA200703009B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
WO2008046573A1 (de) * 2006-10-16 2008-04-24 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
ITMI20072225A1 (it) * 2007-11-23 2009-05-24 Luso Farmaco Inst "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
IT1391236B1 (it) * 2008-07-11 2011-12-01 St Luso Farm D'italia Spa Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso
WO2015155323A1 (en) * 2014-04-10 2015-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Br2 antagonist for use in the prevention of the hypotensive effect of patient treated with angiotensin-converting enzyme inhibitors (acei)
BR112019005167A2 (pt) * 2016-09-16 2019-07-02 Dyax Corp método e kit para analisar uma amostra
AU2018371186B2 (en) 2017-11-24 2022-05-12 Pharvaris Netherlands B.V. Novel bradykinin B2 receptor antagonists
AR118983A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
WO2023180577A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Therapeutic uses of bradykinin b2-receptor antagonists
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
WO2023180575A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021247A1 (it) * 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction

Also Published As

Publication number Publication date
IL182494A (en) 2011-07-31
JP2008516901A (ja) 2008-05-22
EP1799214A1 (en) 2007-06-27
MX2007004297A (es) 2008-03-11
ZA200703009B (en) 2008-08-27
EA010913B1 (ru) 2008-12-30
ATE381931T1 (de) 2008-01-15
GEP20115322B (en) 2011-11-10
AU2005293881B2 (en) 2010-02-25
EP1799214B8 (en) 2008-06-18
US7645759B2 (en) 2010-01-12
CN101039671B (zh) 2010-10-13
AU2005293881A1 (en) 2006-04-20
IL182494A0 (en) 2007-09-20
DK1799214T3 (da) 2008-05-13
HRP20080107T3 (en) 2008-05-31
CA2583920A1 (en) 2006-04-20
DE602005004039T2 (de) 2009-01-22
DE602005004039D1 (de) 2008-02-07
BRPI0515983A (pt) 2008-08-12
SI1799214T1 (sl) 2008-06-30
WO2006040004A1 (en) 2006-04-20
AR051392A1 (es) 2007-01-10
HK1107263A1 (en) 2008-04-03
US20070281944A1 (en) 2007-12-06
CA2583920C (en) 2013-02-12
PT1799214E (pt) 2008-03-31
MA29007B1 (fr) 2007-11-01
UA86091C2 (ru) 2009-03-25
EA200700584A1 (ru) 2007-10-26
RS50563B (sr) 2010-05-07
EP1799214B1 (en) 2007-12-26
NZ554469A (en) 2010-02-26
ES2299090T3 (es) 2008-05-16
ITMI20041963A1 (it) 2005-01-15
NO20071840L (no) 2007-04-11
CN101039671A (zh) 2007-09-19
NO339805B1 (no) 2017-02-06
JP4980917B2 (ja) 2012-07-18
PL1799214T3 (pl) 2008-05-30

Similar Documents

Publication Publication Date Title
CY1107254T1 (el) Μη πεπτιδικοι ανταγωνιστες της ωραδυκινινης και φαρμακευτικες συνθεσεις αυτων
DE60309481D1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
DE60218852D1 (de) Verbindungen
NO20052739D0 (no) CCR5-antagonister som medikamenter
AR030504A1 (es) Peptidos ciclicos selectivos
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
NO20052761D0 (no) Spirocykliske cykloheksanderivater.
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20091395L (no) Nye tiofenderivater
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
CY1111767T1 (el) Υδρογονωμενα παραγωγα βενζο[c]θειοφαινιου ως ανοσορρυθμιστες
ATE464307T1 (de) Mif-hemmer
CY1107368T1 (el) Νεα παραγωγα 4-βενζυλιδενο-πιπεριδινης
NL1023157A1 (nl) Stabilisatormengsels.
DK1499316T3 (da) (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
BRPI0414599A (pt) pirrol-indóis substituìdos
ATE482932T1 (de) N-alkynyl-2-(substituierte aryloxy)alkylthioamide derivate als fungizide
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
DE502006004472D1 (de) Organische elektrolumineszenzvorrichtungen
CY1112103T1 (el) Αντιογκικες ενωσεις διϋδροπυραν-2-ονης
DE602005007364D1 (de) Peptidcyclisierung
ATE441647T1 (de) N-amidderivate von 8-azabicycloä3.2.1üoct-3-yl als ccr1-antagonisten
ITMI20031292A1 (it) Derivati biciclici nk-2 antagonisti selettivi.
EA200600116A1 (ru) Масляный суспензионный концентрат, содержащий дифлуфеникан
NO20053598L (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.